Norwegian biotechnology company Aker BioMarine has signed a long-term global supply agreement with Valensa International for the use of Superba™ in Krill Oil Joint Health and Eye Health products where Aker BioMarine will be the exclusive supplier of krill oil. Under the agreement, Aker BioMarine and Valensa will also jointly perform clinical studies to document the unique properties of Superba™ Krill Oil as an ingredient in Valensa’s patented and patent-pending formulations.
“We are very excited about the opportunity to work with Valensa, and this agreement marks the entry of Superba™ Krill Oil into the Joint Health market, the largest category of dietary supplements, representing USD 3.4 billion in US alone”, said Matts Johansen, Aker BioMarine’s EVP of Sales and Marketing. “As such, joint health is close to 300% larger than the cardiovascular health category and obviously an interesting market for us to enter into”.
Valensa will use Superba™ Krill Oil in their condition-specific dietary supplement formulas in conjunction with several of their own proprietary ingredients, such as Zanthin® Natural Astaxanthin. In a separate press release issued by Valensa, CEO Dr. Rudi E. Moerck, cites “the increased potency of formulas containing krill [that allows] formulators and marketers to reduce the size of their softgels and reduce the ‘pill burden’ on people” as one of the key reasons for using Superba™ Krill Oil in Valensa’s proprietary formulations”.
“I am pleased that Valensa has chosen Superba™ Krill Oil”, says Hallvard Muri, CEO of Aker BioMarine. “Very much like us, Valensa has taken a pharmaceutical-like approach to dietary supplements when it comes to quality and clinical documentation. In Valensa, we have a strong partner with complementary values. As we do with all of our customers, we are very much looking forward to contributing to Valensa’s continued success in marketing and selling their Superba™ Krill Oil-based products to the consumer”.
About Valensa International
Headquartered in Eustis, Florida USA (near Orlando), Valensa International is a leading science-based developer and provider of high quality nature-sourced products for nutritional supplements and functional foods. Valensa’s certified organic production facilities are located in a protected pine/saw palmetto grove.
Valensa Omega-3 brands include Tresalbio™ Supercritical Chia Seed Extract ChiaGold™ Stabilized Chia Seed Oil, ChiaMax™ Low-Fat Whole Grain, Z-Omega™3-6-9, Cranberol® Cranberry Seed Extract and AstaCran® Astaxanthin-Cranberry Seed Extract. Other branded ingredients include Zanthin® Natural Astaxanthin, SpiruZan™ Spirulina & Astaxanthin Complex, USPlus® Prostate Formula and Palmetto Rosso™ Saw Palmetto Extracts. Functional food brands include ChiaMax™ Omega-3 Low-Fat Whole Grain products. Condition-specific brands include Cran-Gyn™ Women’s Health Formula and Nanocosanol™ Policosanol Dispersion. Valensa is committed to production and processing that supports the environment and fair labor practices for those that work the land and participate in the production process.
About Aker BioMarine
Aker BioMarine uses proprietary EcoHarvesting™ technology to sustainably harvest Antarctic krill (Euphausia superba). Aker BioMarine develops, manufactures, and markets Superba™ Krill − high-quality phospholipid-bound omega-3 krill-derived nutraceutical products that have demonstrated higher uptake and utilization in pre-clinical and clinical studies. The company also offers Qrill™ − a krill-derived functional feed that has been demonstrated to significantly promote health and growth in various farmed fish and shrimp species.
Aker BioMarine is listed on the Oslo Stock Exchange (OSE:AKBM) and is owned 83.2% by Aker ASA. Founded in 1841, Aker controls companies with an aggregate of 26,500 employees and more than USD 10 billion of revenues in 2008.